StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

Equities researchers at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright decreased their price target on DBV Technologies from $10.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th.

DBV Technologies Trading Down 2.0 %

Shares of NASDAQ DBVT opened at $0.58 on Tuesday. The firm has a market cap of $111.40 million, a P/E ratio of -1.43 and a beta of 0.73. The business’s 50 day moving average is $0.73 and its 200-day moving average is $0.82. DBV Technologies has a 1-year low of $0.42 and a 1-year high of $2.26.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. The business had revenue of $8.88 million for the quarter, compared to the consensus estimate of $1.10 million. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. During the same quarter in the prior year, the business posted ($0.23) earnings per share. Analysts forecast that DBV Technologies will post -0.61 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Yiheng Capital Management L.P. increased its holdings in shares of DBV Technologies by 6.2% during the first quarter. Yiheng Capital Management L.P. now owns 5,568,909 shares of the company’s stock worth $4,172,000 after buying an additional 327,345 shares in the last quarter. Optiver Holding B.V. increased its holdings in DBV Technologies by 595.2% in the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after purchasing an additional 235,337 shares in the last quarter. Landscape Capital Management L.L.C. bought a new position in DBV Technologies in the third quarter valued at about $94,000. Finally, Cowen AND Company LLC bought a new stake in shares of DBV Technologies during the fourth quarter worth about $49,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.